Assessment of Probability of Pulmonary Fibrosis Progression in Patients with Interstitial Lung Diseases to Determine Further Treatment Tactics
https://doi.org/10.58838/2075-1230-2024-102-3-34-40
Abstract
The objective: to develop a method for assessing the probability of progression of pulmonary fibrosis in patients with interstitial lung diseases in order to determine further treatment tactics.
Subjects and Methods. 80 patients with interstitial lung diseases underwent lung biopsies with consequent morphological and immunohistochemical tests. The group with progressive fibrosis consisted of 42 patients. The prognostic model was built using the binary logistic regression method.
Results. A statistical model was developed in the form of a regression equation consisting of 3 parameters: the presence of a morphological pattern of interstitial fibrosis; intensity of CTGF expression; and intensity of TGF-β expression. This mathematical model makes it possible to predict the progression of pulmonary fibrosis in patients with interstitial lung diseases with 83.3% sensitivity and 84.2% specificity.
About the Authors
A. A. Lukashevich
Belarusian State Medical University
Belarus
Belarus
Anastasia A. Lukashevich, Assistant of Pathological Anatomy Department
83 Dzerzhinskogo Ave., Minsk, 220083
Phone: + 375 (17) 252-12-01
O. A. Yudina
Republican Clinical Medical Center Administration of President of Belarus
Belarus
Belarus
Olga A. Yudina, Candidate of Medical Sciences,
Morbid Anatomist
81/5 ag. Zhdanovichi, Minsk District, Minsk Region, 223052
Phone: + 375 (17) 543-44-44
L. S. Bogush
Republican Scientific and Practical Center of Pulmonology and Phthisiology
Belarus
Belarus
Lyudmila S. Bogush, Candidate of Medical Sciences, Associate Professor, Leading Researcher
157 Dolginovsky Road, Minsk, 220053
Phone: + 375 (17) 373-87-95
E. I. Davidovskaya
Republican Scientific and Practical Center of Pulmonology and Phthisiology
Belarus
Belarus
Elena I. Davidovskaya, Candidate of Medical Sciences, Associate Professor,Head of Department of Pulmonology and Surgical Treatment of Respiratory Diseases
157 Dolginovsky Road, Minsk, 220053
Phone: + 375 (17) 373-87-95
M. I. Dyusmikeeva
Republican Scientific and Practical Center of Pulmonology and Phthisiology
Belarus
Belarus
Marina I. Dyusmikeeva, Candidate of Medical Sciences, Associate Professor, Head of Autopsy Department
157 Dolginovsky Road, Minsk, 220053
Phone: + 375 (17) 373-87-95
A. F. Belko
Republican Scientific and Practical Center of Pulmonology and Phthisiology
Belarus
Belarus
Anna F. Belko, Researcher
157 Dolginovsky Road, Minsk, 220053
Phone: + 375 (17) 373-87-95
References
1. Glinskaya T.N. Incidence of respiratory diseases in the population above the working age in the Republic of Belarus. Voprosy Organizatsii I Informatizatsii Zdravookhraneniya, 2022, no. 3, pp. 18-31. (In Russ.)
2. Arnott J.A., Lambi A.G., Mundy C. et al. The role of connective tissue growth factor (CTGF/CCN2) in skeletogenesis. Critical Reviews in Eukaryotic Gene Expression, 2011, vol. 21, no. 1, pp. 43-69.
3. Behr J., Günther A., Bonella F. German guideline for idiopathic pulmonary fibrosis. Pneumologie, 2020, vol. 74, pp. 263-293.
4. Bradley B., Branley H.M., Egan J.J. et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax, 2008, vol. 63, suppl. 5, pp. 1-58.
5. Cottin V., Hirani N.A., Hotchkin D.L. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur. Respir. Rev., 2018, vol. 27, no. 150, pp. 180076. https://doi.org/10.1183/16000617.0076-2018
6. Flaherty K.R., Brown K.K., Wells A.U. et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir. Res., 2017, vol. 4, no. 1, pp. e000212. https://doi.org/10.1136/bmjresp-2017-000212.
7. Fujita M., Shannon J.M., Morikawa O., Gauldie J., Hara N., Mason R.J. Overexpression of tumor necrosis factor-α diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-β. Am. J. Respir. Cell Mol. Biol., 2003, vol. 29, pp. 669-676.
8. Hinck A.P., Mueller T.D., Springer T.A. Structural biology and evolution of the TGF-β family. Cold Spring Harbor Perspectives In Biology, 2016, vol. 8, no. 12, pp. a022103. https://doi.org/10.1101/cshperspect.a022103
9. Kreuter M., Muller-Ladner U., Costabel U. The diagnosis and treatment of pulmonary fibrosis. Dtsch. Arztebl. Int., 2021, vol. 118, no. 9, pp. 152-162.
10. Kreuter M., Walscher J., Behr J. Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now. Curr. Opin. Pulm. Med., 2017, vol. 23, no. 5, pp. 418-425.
11. Travis W.D., Costabel U., Hansell D.M. et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med., 2013, vol. 188, no. 6, pp. 733-748.
12. Wells A.U., Brown K.K., Flaherty K.R. et al. What's in a name? That which we call IPF, by any other name would act the same. Eur. Respir. J., 2018, vol. 51, no. 5, pp. 1800692. https://doi.org/10.1183/13993003.00692-2018
13. White E., Thomas M., Stowasser S. Challenges for Clinical Drug Development in Pulmonary Fibrosis. Front. Farmacol., 2022, no. 13, pp. 823085. https://doi.org/10.3389/fphar.2022.823085
14. Wollin L., Distler J., Redente E. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur. Respir. J., 2019, vol. 54, no. 3, pp. 1900161. https://doi.org/10.1183/13993003.00161-2019
Review
For citations:
Lukashevich A.A., Yudina O.A., Bogush L.S., Davidovskaya E.I., Dyusmikeeva M.I., Belko A.F. Assessment of Probability of Pulmonary Fibrosis Progression in Patients with Interstitial Lung Diseases to Determine Further Treatment Tactics. Tuberculosis and Lung Diseases. 2024;102(3):34-40. (In Russ.) https://doi.org/10.58838/2075-1230-2024-102-3-34-40
Views:
431
Email this article 